Pharmaceutical Disease Analysis l Report Store l Pharma Intelligence

Disease Analysis: Non-Alcoholic Steatohepatitis (NASH)

The diagnosis of non-alcoholic fatty liver disease (NAFLD) requires evidence of hepatic steatosis and the lack of secondary causes of liver fat accumulation such as substantial alcohol consumption, long-term use of a steatogenic medicine, or monogenic hereditary disorders. NASH is a more advanced form of NAFLD where there is liver inflammation with hepatocyte injury, which can lead to hepatic fibrosis. Although the presence of fibrosis is not required for a diagnosis of NASH, fibrosis is present in over 80% of NASH patients. For this reason, NASH patients are often further segmented by their fibrosis stage. Detection of fibrosis is important as it is linked to worse outcomes for patients.

Disease analysis

Disease Analysis: Non-Alcoholic Steatohepatitis (NASH)

Disease Analysis: Psoriatic Arthritis

Disease Analysis: Rheumatoid Arthritis

Disease Analysis: Ulcerative Colitis

Disease Analysis: Bladder Cancer

Disease Analysis: Osteoporosis

Disease Analysis: Hepatitis C

Disease Analysis: Renal Cell Carcinoma (RCC)

Disease Analysis: Non-Small Cell Lung Cancer (NSCLC)

Disease Analysis: Hemophilia

Disease Analysis: Migraine

Disease Analysis: Crohn’s Disease

Disease Analysis: Dyslipidemia

Disease Analysis: Alzheimer’s Disease

Disease Analysis: Human Papillomavirus (HPV) Vaccines